A Double-Blind, Placebo-Controlled, Evaluation of the Safety and Efficacy of Cariprazine in Patients With Acute Mania Associated With Bipolar I Disorder.

Trial Profile

A Double-Blind, Placebo-Controlled, Evaluation of the Safety and Efficacy of Cariprazine in Patients With Acute Mania Associated With Bipolar I Disorder.

Completed
Phase of Trial: Phase III

Latest Information Update: 09 May 2018

At a glance

  • Drugs Cariprazine (Primary)
  • Indications Bipolar I disorders
  • Focus Registrational; Therapeutic Use
  • Sponsors Forest Laboratories
  • Most Recent Events

    • 09 May 2018 Results (n=1037) of post hoc analysis of pooled data from 3 studies (NCT00488618, NCT01058096 and NCT01058668) presented at the 171st Annual Meeting of the American Psychiatric Association
    • 09 Nov 2017 Results of pooled data from 6 trial (RGH-MD-31, RGH-MD-32, RGH-MD-33, RGH-MD-04, RGH-MD-05 and RGH-MD-16) assessing global improvement with cariprazine in the treatment of biploar I disorder and schizophrenia, were published in the International Journal of Clinical Practice.
    • 01 Jun 2017 Results (n=1065) of a pooled post hoc analysis of RGH-MD31, RGH-MD32 and RGH-MD33 trials, published in the Journal of Affective Disorders
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top